Despite an overwhelming majority of rheumatologists reporting comfort and familiarity with biosimilars, 65% said they are “unlikely” to switch their patients from reference products until there is greater payer adoption, according to data.
In a new report on 2022 trends in biosimilar use released by multinational health care services company Cardinal Health, 98% of surveyed rheumatologists stated they were somewhat or very familiar with biosimilars, while 90% expressed they were somewhat or very comfortable prescribing biosimilars. However, most seem reluctant to use biosimilar